EGFR  ||| S:0 E:5 ||| NNP
mutation  ||| S:5 E:14 ||| NN
testing  ||| S:14 E:22 ||| NN
in  ||| S:22 E:25 ||| IN
non-small  ||| S:25 E:35 ||| JJ
cell  ||| S:35 E:40 ||| NN
lung  ||| S:40 E:45 ||| NN
cancer  ||| S:45 E:52 ||| NN
( ||| S:52 E:53 ||| -LRB-
NSCLC ||| S:53 E:58 ||| NNP
)  ||| S:58 E:60 ||| -RRB-
Lung  ||| S:60 E:65 ||| NNP
carcinoma  ||| S:65 E:75 ||| NN
is  ||| S:75 E:78 ||| VBZ
subdivided  ||| S:78 E:89 ||| VBN
into  ||| S:89 E:94 ||| IN
small  ||| S:94 E:100 ||| JJ
cell  ||| S:100 E:105 ||| NN
carcinoma  ||| S:105 E:115 ||| NNS
and  ||| S:115 E:119 ||| CC
non-small  ||| S:119 E:129 ||| JJ
cell  ||| S:129 E:134 ||| NN
carcinoma  ||| S:134 E:144 ||| NNS
( ||| S:144 E:145 ||| -LRB-
NSCLC ||| S:145 E:150 ||| NNP
) ||| S:150 E:151 ||| -RRB-
.  ||| S:151 E:153 ||| .
NSCLC  ||| S:153 E:159 ||| NNP
is  ||| S:159 E:162 ||| VBZ
heterogeneous  ||| S:162 E:176 ||| JJ
group  ||| S:176 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
carcinomas  ||| S:185 E:196 ||| NN
and  ||| S:196 E:200 ||| CC
accounts  ||| S:200 E:209 ||| NNS
for  ||| S:209 E:213 ||| IN
70-80 ||| S:213 E:218 ||| CD
%  ||| S:218 E:220 ||| NN
of  ||| S:220 E:223 ||| IN
lung  ||| S:223 E:228 ||| NN
cancer ||| S:228 E:234 ||| NN
.  ||| S:234 E:236 ||| .
NSCLC  ||| S:236 E:242 ||| NNP
is  ||| S:242 E:245 ||| VBZ
further  ||| S:245 E:253 ||| RB
divided  ||| S:253 E:261 ||| VBN
into  ||| S:261 E:266 ||| IN
adenocarcinoma ||| S:266 E:280 ||| NN
,  ||| S:280 E:282 ||| ,
squamous  ||| S:282 E:291 ||| JJ
cell  ||| S:291 E:296 ||| NN
carcinoma ||| S:296 E:305 ||| NN
,  ||| S:305 E:307 ||| ,
and  ||| S:307 E:311 ||| CC
large  ||| S:311 E:317 ||| JJ
cell  ||| S:317 E:322 ||| NN
carcinoma ||| S:322 E:331 ||| NN
.  ||| S:331 E:333 ||| .
Activating  ||| S:333 E:344 ||| JJ
somatic  ||| S:344 E:352 ||| JJ
mutations  ||| S:352 E:362 ||| NNS
of  ||| S:362 E:365 ||| IN
the  ||| S:365 E:369 ||| DT
tyrosine  ||| S:369 E:378 ||| JJ
kinase  ||| S:378 E:385 ||| JJ
domain  ||| S:385 E:392 ||| NN
of  ||| S:392 E:395 ||| IN
epidermal  ||| S:395 E:405 ||| JJ
growth  ||| S:405 E:412 ||| NN
factor  ||| S:412 E:419 ||| NN
receptor  ||| S:419 E:428 ||| NN
( ||| S:428 E:429 ||| -LRB-
EGFR ||| S:429 E:433 ||| NNP
)  ||| S:433 E:435 ||| -RRB-
have  ||| S:435 E:440 ||| VBP
recently  ||| S:440 E:449 ||| RB
been  ||| S:449 E:454 ||| VBN
characterized  ||| S:454 E:468 ||| VBN
in  ||| S:468 E:471 ||| IN
a  ||| S:471 E:473 ||| DT
subset  ||| S:473 E:480 ||| NN
of  ||| S:480 E:483 ||| IN
patients  ||| S:483 E:492 ||| NNS
with  ||| S:492 E:497 ||| IN
non-small  ||| S:497 E:507 ||| JJ
cell  ||| S:507 E:512 ||| NN
lung  ||| S:512 E:517 ||| NN
cancer  ||| S:517 E:524 ||| NN
( ||| S:524 E:525 ||| -LRB-
NSCLC ||| S:525 E:530 ||| NNP
) ||| S:530 E:531 ||| -RRB-
.  ||| S:531 E:533 ||| .
These  ||| S:533 E:539 ||| DT
mutations  ||| S:539 E:549 ||| NNS
involve  ||| S:549 E:557 ||| VBP
exons  ||| S:557 E:563 ||| RB
18 ||| S:563 E:565 ||| CD
,  ||| S:565 E:567 ||| ,
19 ||| S:567 E:569 ||| CD
,  ||| S:569 E:571 ||| ,
20  ||| S:571 E:574 ||| CD
and  ||| S:574 E:578 ||| CC
21 ||| S:578 E:580 ||| CD
.  ||| S:580 E:582 ||| .
Patients  ||| S:582 E:591 ||| NNS
harboring  ||| S:591 E:601 ||| VBG
these  ||| S:601 E:607 ||| DT
mutations  ||| S:607 E:617 ||| NN
in  ||| S:617 E:620 ||| IN
their  ||| S:620 E:626 ||| PRP$
tumors  ||| S:626 E:633 ||| NNS
show  ||| S:633 E:638 ||| VBP
good  ||| S:638 E:643 ||| JJ
response  ||| S:643 E:652 ||| NN
to  ||| S:652 E:655 ||| TO
EGFR  ||| S:655 E:660 ||| NNP
tyrosine  ||| S:660 E:669 ||| FW
kinase  ||| S:669 E:676 ||| FW
inhibitors  ||| S:676 E:687 ||| FW
( ||| S:687 E:688 ||| -LRB-
EGFR-TKIs ||| S:688 E:697 ||| NNP
) ||| S:697 E:698 ||| -RRB-
.  ||| S:698 E:700 ||| .
The  ||| S:700 E:704 ||| DT
aim  ||| S:704 E:708 ||| NN
of  ||| S:708 E:711 ||| IN
this  ||| S:711 E:716 ||| DT
manuscript  ||| S:716 E:727 ||| NN
is  ||| S:727 E:730 ||| VBZ
to  ||| S:730 E:733 ||| TO
provide  ||| S:733 E:741 ||| VB
an  ||| S:741 E:744 ||| DT
overview  ||| S:744 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
EGFR  ||| S:756 E:761 ||| NNP
mutations  ||| S:761 E:771 ||| NNS
in  ||| S:771 E:774 ||| IN
NSCLC  ||| S:774 E:780 ||| NNP
as  ||| S:780 E:783 ||| IN
well  ||| S:783 E:788 ||| RB
as  ||| S:788 E:791 ||| RB
to  ||| S:791 E:794 ||| TO
briefly  ||| S:794 E:802 ||| RB
discuss  ||| S:802 E:810 ||| VB
sample  ||| S:810 E:817 ||| NN
requirements  ||| S:817 E:830 ||| NNS
and  ||| S:830 E:834 ||| CC
testing  ||| S:834 E:842 ||| NN
guidelines  ||| S:842 E:853 ||| NNS
for  ||| S:853 E:857 ||| IN
EGFR  ||| S:857 E:862 ||| NNP
mutation ||| S:862 E:870 ||| NN
.  ||| S:870 E:872 ||| .
